Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arch Biopartners Inc (ARCH.VN)

Arch Biopartners Inc (ARCH.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 40,160
  • Shares Outstanding, K 66,933
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,553 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 2.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $-0.02 on 03/02/26
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend 0.200 on 09/13/00
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

    TSX Bottom 100 Stocks

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.455 +31.87%
on 03/31/26
0.830 -27.71%
on 03/04/26
-0.230 (-27.71%)
since 03/02/26
3-Month
0.455 +31.87%
on 03/31/26
1.450 -58.62%
on 01/12/26
-0.650 (-52.00%)
since 01/02/26
52-Week
0.455 +31.87%
on 03/31/26
1.950 -69.23%
on 06/09/25
-1.220 (-67.03%)
since 04/02/25

Most Recent Stories

More News
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered...

ARCH.VN : 0.600 (+1.69%)
ACHFF : 0.4052 (-1.79%)
Upcoming Meeting Dates - January 26, 2026

Toronto, Ontario--(Newsfile Corp. - January 26, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies...

EQB.TO : 112.70 (+1.46%)
PRME.CN : 0.0550 (unch)
SKRR.VN : 0.250 (-5.66%)
CYF.VN : 0.015 (-25.00%)
NOP.CN : 0.1500 (unch)
AIML.CN : 0.0350 (unch)
CRI.VN : 0.145 (-3.33%)
BLN.TO : 7.05 (-0.14%)
ATI.VN : 0.020 (+33.33%)
PPX.VN : 0.280 (+1.82%)
DFSC.VN : 3.000 (+7.14%)
LOT.VN : 0.055 (-8.33%)
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman...

ARCH.VN : 0.600 (+1.69%)
ACHFF : 0.4052 (-1.79%)
Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated...

ARCH.VN : 0.600 (+1.69%)
ACHFF : 0.4052 (-1.79%)
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

First patient successfully completes dosing at Toronto General Hospital St. Michael’s Hospital is expected to be the next Canadian clinical site activated Arch is looking for additional clinical sites...

ARCH.VN : 0.600 (+1.69%)
ACHFF : 0.4052 (-1.79%)
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled...

ARCH.VN : 0.600 (+1.69%)
ACHFF : 0.4052 (-1.79%)
Jobs Numbers Due in Canada Next Week

U.S. Monday Economic Lookahead S&P final U.S. manufacturing PMI (May) ISM manufacturing ...

CRWD : 399.12 (+1.48%)
PVH : 77.11 (+0.72%)
AVGO : 314.55 (+0.34%)
ARCH.VN : 0.600 (+1.69%)
CRDO : 101.45 (+5.77%)
DLTR : 108.44 (-0.24%)
GHM : 81.25 (-0.73%)
SAIC : 100.11 (+2.87%)
IOT : 32.26 (+1.32%)
FIVE : 235.39 (+0.20%)
GOT.VN : 1.620 (-4.14%)
CPB : 22.01 (-1.65%)
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

ARCH.VN : 0.600 (+1.69%)
ACHFF : 0.4052 (-1.79%)
U.S. Eases into Memorial Day Weekend

MondayU.S.Markets are Closed for Memorial Day TuesdayU.S. Economic Lookahead S&P ...

MOMO : 5.93 (+1.19%)
A : 115.48 (+0.82%)
ARCH.VN : 0.600 (+1.69%)
DAC : 115.43 (+1.12%)
HEI.A : 211.04 (-0.63%)
HPQ : 19.51 (+2.96%)
COST : 1,014.96 (+1.85%)
GCO : 28.39 (-0.73%)
EGT.VN : 0.130 (unch)
DAC.VN : 0.035 (+600.00%)
DELL : 174.37 (+2.95%)
CRM : 187.18 (+0.50%)
Stocks in play: Arch Biopartners Inc.

Announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee ...

ARCH.VN : 0.600 (+1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arch Biopartners Inc is a developer of a therapeutic pipeline designed to address acute kidney injury (AKI) and chronic kidney disease (CKD) by targeting inflammation- and toxin-related kidney damage. The group offers mechanism-based treatments, enabling patients suffering from both acute and chronic...

See More

Key Turning Points

3rd Resistance Point 0.640
2nd Resistance Point 0.620
1st Resistance Point 0.610
Last Price 0.600
1st Support Level 0.580
2nd Support Level 0.560
3rd Support Level 0.550

See More

52-Week High 1.950
Fibonacci 61.8% 1.379
Fibonacci 50% 1.202
Fibonacci 38.2% 1.026
Last Price 0.600
52-Week Low 0.455

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.